0001209191-15-070308.txt : 20150911 0001209191-15-070308.hdr.sgml : 20150911 20150911152005 ACCESSION NUMBER: 0001209191-15-070308 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150909 FILED AS OF DATE: 20150911 DATE AS OF CHANGE: 20150911 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Q Therapeutics, Inc. CENTRAL INDEX KEY: 0001366541 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203708500 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 615 ARAPEEN DRIVE STREET 2: SUITE 102 CITY: SALT LAKE CITY STATE: UT ZIP: 84108 BUSINESS PHONE: (801) 582-5400 MAIL ADDRESS: STREET 1: 615 ARAPEEN DRIVE STREET 2: SUITE 102 CITY: SALT LAKE CITY STATE: UT ZIP: 84108 FORMER COMPANY: FORMER CONFORMED NAME: Q Holdings, Inc. DATE OF NAME CHANGE: 20111208 FORMER COMPANY: FORMER CONFORMED NAME: Grace 2, Inc. DATE OF NAME CHANGE: 20060619 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BORST STEVEN JOHN CENTRAL INDEX KEY: 0001532620 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-52062 FILM NUMBER: 151103304 MAIL ADDRESS: STREET 1: PO BOX 58154 CITY: SALT LAKE CITY STATE: UT ZIP: 84158 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-09-09 0 0001366541 Q Therapeutics, Inc. [NONE] 0001532620 BORST STEVEN JOHN C/O Q THERAPEUTICS, INC. 615 ARAPEEN DRIVE, SUITE 102 SALT LAKE CITY UT 84108 1 1 0 0 Chief Executive Officer Option to Purchase Common Stock 0.70 2015-09-09 4 A 0 400000 0.70 A 2016-09-08 2025-09-08 Common Stock 400000 2536674 D Option to Purchase Common Stock 0.70 2015-09-09 4 A 0 100000 0.70 A 2025-09-08 Common Stock 100000 2636674 D Option to Purchase Common Stock 0.70 2015-09-09 4 A 0 100000 0.70 A 2025-09-08 Common Stock 100000 2736674 D Option shall vest at the rate of 28% on the one year anniversary of the grant date and 2% per month thereafter. Option will vest in full upon the closing of an equity and/or debt financing in the cumulative amount of $10 million on or prior to June 30, 2016. Option to vest in full upon the first patient dosed in the Company's Phase I clinical trial. Steven J. Borst 2015-09-11